Venus Remedies Limited, a research based pharmaceutical company has entered into the super specialty oncology segment with the launch of its new dedicated sub business unit Passion Oncobiz. The new units has a product basket of 21 products in injectable form for fighting practically all types of cancer.

With a well qualified team comprising of 35 professionals, this special marketing cell is aimed at offering affordable life-saving medicines to Indian masses. The business unit will cover entire India including both Government and private institutes to facilitate the therapies for all type of cancer. The company is investing US $ 2 million for the promotion of this sub business unit.

The therapies which will be used in the treatment of cancer will include a product basket of 21 products covering all type of cancer like lung cancer, breast cancer, cervical cancer, brain tumour, oral cancer. All the products are manufactured by the company at its Baddi facility which has many international accreditations to its credit including the European-GMP.

Venus Remedies has already sold some molecules through strategic tie-up arrangements with leading pharmaceutical companies. The reason behind launching Passion Oncobiz is to provide quality product at affordable prices against innovator companies.

Venus Remedies in the recent past in-licensed the technology for solid tumour detection from the University of Illinois, Chicago, which will facilitate the early detection and staging of solid tumours using conventional modes. Venus developed a formulation for this technology which will be used in injectable form as a diagnostic tool for the detection of solid tumours in humans. Intellectual property rights for this product have already been protected by Venus and phase-II clinical trials are under process.

Speaking on the occasion Pawan Chaudhary, CMD Venus Remedies said, “At present, the anti cancer drug segment is contributing 30 per cent of the total sales of the company with more than 100 market authorisations from 25 countries including UK, Germany, Poland, Portugal; and with the launch of Passion Oncobiz, Venus will further reinforce its industry position and expects growth of 10 per cent in the market share by 2015.”

The companies domestic market is growing at an annual rate of around 30 per cent and the estimate of current sales of anti cancer products is $150-200 million a year.